Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Functional asymmetry and essential structural roles of PDE6α and PDE6β subunits in rod-photoreceptor integrity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Light-Activated RPE65 Inhibitors Enable On-Demand Visual Cycle Control.

Journal of the American Chemical Society·2026
Same author

A combinatorial synthetic strategy for developing genome-editing protein-delivery agents targeting mouse retina.

Nature communications·2026
Same author

Age-Driven Lipid Remodeling Activates Lysosome-Mediated Plasma Membrane Repair.

Research square·2026
Same author

Structural analysis of rhodopsin states in megabody complexes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

TIGER: A tdTomato in vivo genome-editing reporter mouse for investigating precision-editor delivery approaches.

Proceedings of the National Academy of Sciences of the United States of America·2025

相关实验视频

Updated: May 12, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.7K

合理设计的,短效RPE65抑制剂用于视觉周期相关的视网膜病变.

Marco Bassetto1,2,3, Yulun Hu4, Bowen Li4

  • 1Department of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, California 92697, United States.

Journal of medicinal chemistry
|August 6, 2025
PubMed
概括

新的视觉循环调节器提供更快的恢复和更少的副作用. 这些短效化合物向RPE65,防止Stargardt病和相关疾病中的视网膜退化.

更多相关视频

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells
07:07

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Published on: March 8, 2015

9.3K
Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling
05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.3K

相关实验视频

Last Updated: May 12, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.7K
Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells
07:07

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Published on: March 8, 2015

9.3K
Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling
05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.3K

科学领域:

  • 生物化学 生化学
  • 眼科医生 眼科 眼科
  • 药理学 药理学 是一个学科.

背景情况:

  • 视觉循环对视力至关重要,但其副产品可能会导致视网膜毒性,以斯特加特病1型 (STGD1) 为例.
  • 针对RPE65的视觉循环调节器 (VCM) 艾米克苏塔 (Emixustat) 抑制了有毒比斯雷类药物的产生,但其作用时间长,导致视力受损.

研究的目的:

  • 开发新型,短效的VCMs,以提高安全性.
  • 为了研究含有的埃米克苏塔特类型的可调节的水解清除和更快的视觉循环恢复.

主要方法:

  • 合成含埃斯特的埃米克苏塔特类似物.
  • 评估RPE65向亲和力和以酶为媒介的新陈代谢.
  • 在体外和体内视觉循环恢复动力学的评估.
  • 在光性视网膜病变和STGD1.1的小鼠模型中测试疗效.

主要成果:

  • 雌激素类似物表现出可调节的新陈代谢,并保持了高亲和度的RPE65向.
  • 化合物6 (EYE-002) 和7 (EYE-003) 显示视觉循环功能恢复速度比emixustat.
  • 这些新型VCM在疾病模型中提供了对视网膜退化的保护.

结论:

  • 基于埃米克苏塔特类似物的短期VCM为视网膜疾病提供了有前途的治疗策略.
  • 可调节的以酶为媒介的清除可以优化作用的持续时间,可能减少视觉副作用.
  • 这些发现突显了受控视觉周期调制在治疗STGD1和相关视网膜病变方面的治疗潜力.